ArticleCancer science2026
SERPINE1 Alternative Polyadenylation Influences Gastric Cancer Prognosis via N6-Methyladenosine Modification.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Alternative polyadenylation (APA) and N6-methyladenosine (m6A) methylation are critical post-transcriptional regulators in cancer, yet their synergistic role in gastric cancer (GC) remains poorly understood. By integrating RNA-seq and MeRIP-seq data from paired GC tumor and adjacent normal tissues, we identified 9769 distinct APA events and 3117 differentially methylated sites. Concurrent 3'UTR length and methylation alterations were observed in 165 genes. Among these, SERPINE1 emerged as an independent prognostic factor; its high expression correlated with advanced TNM stages and poor survival across multiple independent cohorts. Moreover, elevated plasma SERPINE1 protein levels in an in-house cohort of 263 GC patients were significantly associated with worse overall and disease-specific survival. Mechanistically, the APA factor CSTF2 and the m6A reader IGF2BP1 were found to physically interact and cooperatively regulate SERPINE1 3'UTR selection. Silencing either factor shifted expression toward the long 3'UTR isoform and reduced SERPINE1 protein levels. Functional assays further confirmed that the short SERPINE1 isoform promotes GC cell proliferation, migration, and invasion more potently than the long isoform. Collectively, this study reveals that CSTF2 and IGF2BP1 synergistically drive SERPINE1 3'UTR shortening to enhance GC malignancy, highlighting SERPINE1 as a promising prognostic biomarker and potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.